IQVIA Q4 revenue rises 10.3%, beats analyst estimates

Overview

• Clinical research firm's Q4 revenue rose 10.3%, beating analyst expectations

• Adjusted EPS for Q4 beat analyst expectations

• Company repurchased $212 mln of its common stock in Q4

Outlook

• IQVIA expects 2026 revenue between $17,150 mln and $17,350 mln

• Company projects 2026 adjusted EBITDA of $3,975 mln to $4,025 mln

• IQVIA forecasts 2026 adjusted EPS between $12.55 and $12.85

Result Drivers

• R&DS GROWTH - R&DS revenue grew 9.9% year-over-year, driven by strong bookings and backlog growth

• AI AND STRATEGY - Investments in AI innovations and expanded go-to-market strategy led to strong topline growth

• OPERATIONAL DISCIPLINE - Operational discipline contributed to strong financial performance, per CEO Ari Bousbib

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for IQVIA Holdings Inc is $262.50, about 29.6% above its February 4 closing price of $202.54

• The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 17 three months ago

Press Release: ID:nBw6RqB05a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.